688302 Share Price Performance
CN¥0
-33.61 (-100.00%)
Price CN¥0
Share Pricen/a
Hinova Pharmaceuticals Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
688302 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Hinova Pharmaceuticals Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 25, 2026
- -1.46
- 98.56%
- -612.36%
- 9.1%
About 688302
- Founded
- 2013
- Employees
- 174
- CEO
- WebsiteView website
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Hinova Pharmaceuticals Inc. was founded in 2013 and is headquartered in Chengdu, China.
